{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:32:52Z","timestamp":1788172372415,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005721","name":"Universit\u00e4t Bielefeld","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment with short-acting betablockers in septic patients remains controversial. Two recent large multicenter trials have provided additional evidence on this therapeutic approach. We thus performed a meta-analysis, including the most recent data, to evaluate the potential impacts of treatment with short-acting betablockers on mortality in adult septic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The data search included PubMed, Web of Science, ClinicalTrials.gov and the Cochrane Library. A meta-analysis of all eligible peer-reviewed studies was performed in accordance with the PRISMA statement. Only randomized, controlled studies with valid classifications of sepsis and intravenous treatment with short-acting betablockers (landiolol or esmolol) were included. Short-term mortality served as the primary endpoint. Secondary endpoints included effects on short-term mortality regarding patient age and cardiac rhythm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of seven studies summarizing 854 patients fulfilled the predefined criteria and were included. Short-term mortality as well as pooled mortality (longest period of data on mortality) was not significantly impacted by treatment with short-acting betablockers when compared to the reference treatment (Risk difference, \u2212\u20090.10 [95% CI, \u2212\u20090.22 to 0.02]; <jats:italic>p<\/jats:italic>\u2009=\u20090.11; <jats:italic>p<\/jats:italic> for Cochran\u2019s Q test\u2009=\u20090.001; I<jats:sup>2<\/jats:sup>\u2009=\u200973%). No difference was seen when comparing patients aged\u2009&lt;\u200965 versus\u2009\u2265\u200965\u00a0years (<jats:italic>p<\/jats:italic>\u2009=\u20090.11) or sinus tachycardia with atrial fibrillation (<jats:italic>p<\/jats:italic>\u2009=\u20090.27). Despite statistical heterogeneity, no significant publication bias was observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Administration of short-acting betablockers did not reduce short-term mortality in septic patients with persistent tachycardia. Future studies should also provide extensive hemodynamic data to enable characterization of cardiac function before and during treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-024-05174-w","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:21:29Z","timestamp":1732710089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mortality in septic patients treated with short-acting betablockers: a comprehensive meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"28","author":[{"given":"Mihai-Gabriel","family":"Alexandru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Niewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Borgstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Whitehouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"5174_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395:200\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)32989-7.","journal-title":"The Lancet"},{"key":"5174_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/CCM.0000000000003342","volume":"46","author":"CJ Paoli","year":"2018","unstructured":"Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and costs of sepsis in the united states\u2014an analysis based on timing of diagnosis and severity level*. Crit Care Med. 2018;46:1889\u201397. https:\/\/doi.org\/10.1097\/CCM.0000000000003342.","journal-title":"Crit Care Med"},{"key":"5174_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13054-019-2478-6","volume":"23","author":"J-L Vincent","year":"2019","unstructured":"Vincent J-L, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23:196. https:\/\/doi.org\/10.1186\/s13054-019-2478-6.","journal-title":"Crit Care"},{"key":"5174_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10020-019-0132-z","volume":"26","author":"Z Mostel","year":"2020","unstructured":"Mostel Z, Perl A, Marck M, Mehdi SF, Lowell B, Bathija S, et al. Post-sepsis syndrome\u2014an evolving entity that afflicts survivors of sepsis. Mol Med. 2020;26:6. https:\/\/doi.org\/10.1186\/s10020-019-0132-z.","journal-title":"Mol Med"},{"key":"5174_CR5","doi-asserted-by":"publisher","first-page":"A50","DOI":"10.1186\/2197-425X-3-S1-A50","volume":"3","author":"C Fleischmann","year":"2015","unstructured":"Fleischmann C, Hartmann M, Hartog C, Welte T, Heublein S, Thomas-Rueddel D, et al. Epidemiology of sepsis in Germany: incidence, mortality and associated costs of care 2007\u20132013. Intensive Care Med Exp. 2015;3:A50. https:\/\/doi.org\/10.1186\/2197-425X-3-S1-A50.","journal-title":"Intensive Care Med Exp"},{"key":"5174_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jointm.2022.01.004","volume":"2","author":"M Lescroart","year":"2022","unstructured":"Lescroart M, Pequignot B, Kimmoun A, Klein T, Levy B. Beta-blockers in septic shock: What is new? J Intensive Med. 2022;2:150\u20135. https:\/\/doi.org\/10.1016\/j.jointm.2022.01.004.","journal-title":"J Intensive Med"},{"key":"5174_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13054-020-03438-9","volume":"25","author":"SS Scholz","year":"2021","unstructured":"Scholz SS, Borgstedt R, Ebeling N, Menzel LC, Jansen G, Rehberg S. Mortality in septic patients treated with vitamin C: a systematic meta-analysis. Crit Care. 2021;25:17. https:\/\/doi.org\/10.1186\/s13054-020-03438-9.","journal-title":"Crit Care"},{"key":"5174_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.735841","author":"R Bruning","year":"2021","unstructured":"Bruning R, Dykes H, Jones TW, Wayne NB, Sikora Newsome A. Beta-adrenergic blockade in critical illness. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.735841.","journal-title":"Front Pharmacol"},{"key":"5174_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1053\/j.jvca.2019.10.017","volume":"34","author":"A Belletti","year":"2020","unstructured":"Belletti A, Landoni G, Lomivorotov VV, Oriani A, Ajello S. Adrenergic downregulation in critical care: molecular mechanisms and therapeutic evidence. J Cardiothorac Vasc Anesth. 2020;34:1023\u201341. https:\/\/doi.org\/10.1053\/j.jvca.2019.10.017.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"5174_CR10","doi-asserted-by":"publisher","first-page":"A15","DOI":"10.1093\/eurheartj\/sux039","volume":"20","author":"S Rehberg","year":"2018","unstructured":"Rehberg S, Joannidis M, Whitehouse T, Morelli A. Landiolol for managing atrial fibrillation in intensive care. Eur Heart J Suppl. 2018;20:A15\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/sux039.","journal-title":"Eur Heart J Suppl"},{"key":"5174_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jama.2013.278477","volume":"310","author":"A Morelli","year":"2013","unstructured":"Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock. JAMA. 2013;310:1683. https:\/\/doi.org\/10.1001\/jama.2013.278477.","journal-title":"JAMA"},{"key":"5174_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40261-015-0325-3","volume":"35","author":"Z Wang","year":"2015","unstructured":"Wang Z, Wu Q, Nie X, Guo J, Yang C. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective. Randomized Trial Clin Drug Investig. 2015;35:707\u201316. https:\/\/doi.org\/10.1007\/s40261-015-0325-3.","journal-title":"Randomized Trial Clin Drug Investig"},{"key":"5174_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","volume":"8","author":"Y Kakihana","year":"2020","unstructured":"Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al. Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8:863\u201372. https:\/\/doi.org\/10.1016\/S2213-2600(20)30037-0.","journal-title":"Lancet Respir Med"},{"key":"5174_CR14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.2023.20134","volume":"330","author":"T Whitehouse","year":"2023","unstructured":"Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D, et al. Landiolol and organ failure in patients with septic shock. JAMA. 2023;330:1641. https:\/\/doi.org\/10.1001\/jama.2023.20134.","journal-title":"JAMA"},{"issue":"10","key":"5174_CR15","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00134-024-07587-1","volume":"50","author":"S Rehberg","year":"2024","unstructured":"Rehberg S, Frank S, \u010cern\u00fd V, Cihl\u00e1\u0159 R, Borgstedt R, Biancofiore G, et al. Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med. 2024;50(10):1622\u201334. https:\/\/doi.org\/10.1007\/s00134-024-07587-1.","journal-title":"Intensive Care Med"},{"key":"5174_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12871-023-01983-8","volume":"23","author":"J Wang","year":"2023","unstructured":"Wang J, Gao X, He Z, Wang J, Xu G, Li T. Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography\u2014a randomized controlled trial. BMC Anesthesiol. 2023;23:51. https:\/\/doi.org\/10.1186\/s12871-023-01983-8.","journal-title":"BMC Anesthesiol"},{"key":"5174_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/SHK.0000000000001905","volume":"57","author":"MN Cocchi","year":"2022","unstructured":"Cocchi MN, Dargin J, Chase M, Patel PV, Grossestreuer A, Balaji L, et al. Esmolol to treat the hemodynamic effects of septic shock: a randomized controlled trial. Shock. 2022;57:508\u201317. https:\/\/doi.org\/10.1097\/SHK.0000000000001905.","journal-title":"Shock"},{"key":"5174_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3760\/cma.j.issn.2095-4352.2014.10.007","volume":"26","author":"S Yang","year":"2014","unstructured":"Yang S, Liu Z, Yang W, Zhang G, Hou B, Liu J, et al. Effects of the \u03b2-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26:714\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.2095-4352.2014.10.007.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"5174_CR19","first-page":"759","volume":"27","author":"L Xinqiang","year":"2015","unstructured":"Xinqiang L, Weiping H, Miaoyun W, Wenxin Z, Wenqiang J, Shenglong C, et al. Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015;27:759\u201363.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"5174_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3760\/cma.j.issn.2095-4352.2017.05.002","volume":"29","author":"S Wang","year":"2017","unstructured":"Wang S, Li M, Duan J, Yi L, Huang X, Chen D, et al. Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017;29:390\u20135. https:\/\/doi.org\/10.3760\/cma.j.issn.2095-4352.2017.05.002.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"issue":"17","key":"5174_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3760\/cma.j.issn.0376-2491.2019.17.009","volume":"99","author":"H Liu","year":"2019","unstructured":"Liu H, Ding XF, Zhang SG, Wang HX, Luo YG, Duan XG, Liu SH, Zhang RF, Zhang XJ, Qin CH, Han B, Wang Y, Sun TW. Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2019;99(17):1317\u201322. https:\/\/doi.org\/10.3760\/cma.j.issn.0376-2491.2019.17.009. (Chinese).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"5174_CR22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.4103\/0366-6999.185856","volume":"129","author":"W Du","year":"2016","unstructured":"Du W, Wang X-T, Long Y, Liu D-W. Efficacy and safety of esmolol in treatment of patients with septic shock. Chin Med J (Engl). 2016;129:1658\u201365. https:\/\/doi.org\/10.4103\/0366-6999.185856.","journal-title":"Chin Med J (Engl)"},{"key":"5174_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4103\/0970-9185.169063","volume":"31","author":"C Chacko","year":"2015","unstructured":"Chacko C, Gopal S. Systematic review of use of \u03b2-blockers in sepsis. J Anaesthesiol Clin Pharmacol. 2015;31:460. https:\/\/doi.org\/10.4103\/0970-9185.169063.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"5174_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1185\/03007995.2015.1062357","volume":"31","author":"F Sanfilippo","year":"2015","unstructured":"Sanfilippo F, Santonocito C, Morelli A, Foex P. Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin. 2015;31:1817\u201325. https:\/\/doi.org\/10.1185\/03007995.2015.1062357.","journal-title":"Curr Med Res Opin"},{"key":"5174_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1080\/07853890.2022.2098376","volume":"54","author":"M Heliste","year":"2022","unstructured":"Heliste M, Pettil\u00e4 V, Berger D, Jakob SM, Wilkman E. Beta-blocker treatment in the critically ill: a systematic review and meta-analysis. Ann Med. 2022;54:1994\u20132010. https:\/\/doi.org\/10.1080\/07853890.2022.2098376.","journal-title":"Ann Med"},{"key":"5174_CR26","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.chest.2021.01.009","volume":"159","author":"D Hasegawa","year":"2021","unstructured":"Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Takahashi K, Yatabe T, et al. Effect of ultrashort-acting \u03b2-blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation. Chest. 2021;159:2289\u2013300. https:\/\/doi.org\/10.1016\/j.chest.2021.01.009.","journal-title":"Chest"},{"key":"5174_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"key":"5174_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s13063-018-3024-6","volume":"19","author":"M Unger","year":"2018","unstructured":"Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19:637. https:\/\/doi.org\/10.1186\/s13063-018-3024-6.","journal-title":"Trials"},{"key":"5174_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043194","volume":"11","author":"R Lall","year":"2021","unstructured":"Lall R, Mistry D, Skilton E, Boota N, Regan S, Bion J, et al. Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial. BMJ Open. 2021;11: e043194. https:\/\/doi.org\/10.1136\/bmjopen-2020-043194.","journal-title":"BMJ Open"},{"key":"5174_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100571","volume":"28","author":"N Matsuda","year":"2020","unstructured":"Matsuda N, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, et al. Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study. EClinicalMedicine. 2020;28: 100571. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100571.","journal-title":"EClinicalMedicine"},{"key":"5174_CR31","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1097\/CCM.0b013e31828a678d","volume":"41","author":"A Morelli","year":"2013","unstructured":"Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock. Crit Care Med. 2013;41:2162\u20138. https:\/\/doi.org\/10.1097\/CCM.0b013e31828a678d.","journal-title":"Crit Care Med"},{"key":"5174_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jama.2023.27647","volume":"331","author":"K Mantzarlis","year":"2024","unstructured":"Mantzarlis K, Vazgiourakis V, Makris D. Use of landiolol for patients with septic shock and organ failure. JAMA. 2024;331:705. https:\/\/doi.org\/10.1001\/jama.2023.27647.","journal-title":"JAMA"},{"key":"5174_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/CIR.0000000000001263","volume":"2024","author":"JA Joglar","year":"2023","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2023;2024:149. https:\/\/doi.org\/10.1161\/CIR.0000000000001263.","journal-title":"Circulation"},{"key":"5174_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.116.232884","volume":"359","author":"S Nasrollahi-Shirazi","year":"2016","unstructured":"Nasrollahi-Shirazi S, Sucic S, Yang Q, Freissmuth M, Nanoff C. Comparison of the -adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359:73\u201381. https:\/\/doi.org\/10.1124\/jpet.116.232884.","journal-title":"J Pharmacol Exp Ther"},{"key":"5174_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00228-016-2176-0","volume":"73","author":"G Krumpl","year":"2017","unstructured":"Krumpl G, Ulc I, Trebs M, Kadlecov\u00e1 P, Hodisch J. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73:417\u201328. https:\/\/doi.org\/10.1007\/s00228-016-2176-0.","journal-title":"Eur J Clin Pharmacol"},{"key":"5174_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11886-020-01277-2","volume":"22","author":"M L\u2019Heureux","year":"2020","unstructured":"L\u2019Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep. 2020;22:35. https:\/\/doi.org\/10.1007\/s11886-020-01277-2.","journal-title":"Curr Cardiol Rep"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-05174-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-05174-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:09:33Z","timestamp":1732712973000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-05174-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5174"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-05174-w","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"28 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"All authors have read and approved the submission of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.A., P.N., S.K., R.B., and S.S.S. report no competing interests. S. R. served as a speaker for AOP Health. T.W. was the Chief Investigator for STRESS\u2010L which was funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (Project Number: EME\u201014\/150\/85) and during the conduct of the study, he received personal fees and non\u2010financial support from AOP Orphan, manufacturer of landiolol. M.S. (or Institution) receives funding for studies, advisory board or speaker fees from the NIHR, Medical Research Council, AOP Pharma, Aptarion, Biomerieux, Biotest, deePull, Deltex Medical, Gentian, Matisse, Roche Diagnostics, Safeguard Biosystems, Volition. Singer is Sepsis Topic Advisor for NICE and sits on the council of the International Sepsis Forum.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}